In this article, we look at the 10 Best Australian Stocks To Buy According to Hedge Funds.

A Look at Australia’s Economic Performance in 2024

According to a report by KPMG, the global economy has shown remarkable resilience during monetary policy tightening and ongoing geopolitical tensions. In contrast, the Australian economy was close to entering a recession in 2024, with a mere 0.1% growth in the first quarter. Over the past year, the economy grew by only 1.1%. Household consumption increased by 0.4% during Q1, slightly better than Q4 of 2023. However, labor productivity, measured as GDP per hour worked, remained stagnant as the growth in hours worked matched GDP growth. The mining sector plays a crucial role in the economy of Australia making up 14.3% of the industry’s output, while finance contributes 7.4%, and manufacturing and construction add 7.1% and 5.7%, respectively. Australia’s export market is primarily driven by its mining resources, with China being the largest destination, accounting for 32.4% of exports, followed by Japan at 13.1%.

The March 2024 survey of private capital expenditure reveals strong actual investments in the first nine months of FY24, along with positive momentum for the remainder of the financial year and into FY25. Private new capital expenditure rose by 1% in the March quarter of 2024. Business investment in non-mining industries grew by 3.3%, partially offsetting a 4.7% decline in mining capital expenditure. This quarterly growth marks a slowdown from the robust levels seen in late 2022 and early 2023. The transport, postal, and warehousing sectors experienced the strongest growth, driven by increased vehicle investments and ongoing spending on large infrastructure projects. Similarly, capital expenditure on equipment and machinery in the information media and telecommunications sector rose significantly due to continued investment in data centers. However, the weakening demand for consumer goods and services impacted the retail sector and its upstream industries.

Australian Equities vs. U.S. Stocks 

Chris Leithner, joint managing director at Leithner & Co. investment company, is bullish on Australian equities and expects the market to outperform the S&P 500’s returns in coming years. According to him, over the past decade and more, the total returns of the All Ordinaries and ASX 200 indexes, have underperformed the S&P 500 Index. Some analysts, such as Roger Montgomery, attribute this underperformance to Australian companies’ overly generous dividend payments, inadequate earnings retention, and restricted capital expenditure. However, Leithner disagrees and says that a significant factor of this underperformance is the difference in earnings growth between the two markets. American stocks have benefited from substantial earnings growth, partly driven by debt-financed share buybacks, leading to higher debt-to-equity and CAPE ratios. In contrast, Australian equities have experienced a decline in CPI-adjusted earnings per share (EPS), as share buybacks have not played the same role. As a result, Australian companies are more conservatively financed and offer superior medium and long-term prospects. This analysis suggests that while American equities have generated significant rewards since the Global Financial Crisis (GFC), they also pose considerable risks at current prices. Conversely, Australian equities, despite their recent underperformance, are better positioned for future growth due to their robust financial foundation and conservative pricing.

Share buybacks have dramatically increased over the years, with S&P 500 companies repurchasing a staggering $825 billion worth of stock in the 12 months leading up to January 2024. This is part of a broader trend that has seen buybacks rise from an average of around $200 billion per year in the early 1990s to over $1 trillion per year before the COVID-19 pandemic. While buybacks can boost earnings per share (EPS) by reducing the number of shares outstanding, they also artificially inflate the growth of earnings. For instance, a company that repurchases shares can show a much higher EPS growth rate than its net profit after tax growth rate. While this inflation of earnings through buybacks is significant, research suggests that buybacks have contributed between 30-40% of the long-term EPS growth of the S&P 500, with some estimates as high as 71%. The cumulative effect of these repurchases is immense, with S&P 500 companies buying back a CPI-adjusted total of $17.7 trillion worth of shares since 1990, an amount equivalent to nearly 45% of the current U.S. GDP.

The leverage used to finance these buybacks is also noteworthy. In contrast to Australian companies, which have a relatively low debt-to-equity ratio and conduct minimal buybacks, U.S. companies have significantly increased their leverage over the past two decades, with the debt-to-equity ratio surpassing above 80% in recent years. This increased leverage, coupled with the substantial buybacks, has led to a higher cyclically adjusted price-to-earnings (CAPE) ratio for the S&P 500 compared to the All Ordinaries Index in Australia. As a result, while the S&P 500 has outperformed the All Ords in recent years, the high CAPE ratio suggests that future returns for the S&P 500 may be lower, while the Australian shares may offer better medium- to long-term prospects.

According to IG’s biannual Client Sentiment Survey, Australian traders are bullish towards the S&P/ASX 200, with 65% expecting a rise in the next six months. Despite this confidence, there is a noticeable shift towards international markets, particularly in the United States, where many traders believe the Nasdaq will outperform the ASX 200. Australian traders have nearly doubled their focus on US markets over the past six months. International markets provide exposure to a broader range of industries, especially in technology and growth stocks, and offer opportunities for risk management and enhanced returns. Australia’s market lacks diversity, by fostering innovation and supporting emerging industries the market could attract more local investment.

While the global economy demonstrates resilience, Australia’s economic performance in 2024 has been less robust. The mining sector continues to be a key driver, alongside finance and infrastructure investments, but the broader economy faces challenges, particularly in retail and upstream industries. However, the outlook for the remainder of FY24 and into FY25 remains cautiously optimistic, with private capital expenditure showing some positive momentum. With that in context, let’s take a look at the 10 best Australian stocks to buy according to hedge funds.

Our Methodology

For this article, we used Finviz and Yahoo Finance stock screeners plus online rankings to compile an initial list of the 30 largest companies in Australia by market cap. From that list, we narrowed our choices to the 10 stocks according to their hedge fund sentiment, which was taken from our database of 912 elite hedge funds as of Q2 of 2024. We also included the market cap of these companies as of August 30. The list is sorted in ascending order of their hedge fund sentiment, as of June 30.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

10 Best Australian Stocks To Buy According to Hedge Funds

10. NOVONIX (NASDAQ:NVX)  

Number of Hedge Fund Holders: 3  

Market Capitalization as of August 30: $194.27 Million  

NOVONIX (NASDAQ:NVX) is a leading company operating in the battery technology sector. The company is driving innovation in the global lithium-ion battery industry with cutting-edge, sustainable technologies, high-performance materials, and enhanced production methods. The company produces battery cell testing equipment and high-performance synthetic graphite anode materials. The company has established itself as a key player in the battery industry for electric vehicles and energy storage solutions. NOVONIX (NASDAQ:NVX) has operations in Australia, Canada, and the United States. The company has evolved from its early focus on Ultra-High Precision Coulometry (UHPC) systems and aims to become a leading supplier of advanced battery technologies.

For the quarter ending June 30, NOVONIX (NASDAQ:NVX)  reported several key developments across its divisions. In the Anode Materials segment, the company was selected to receive $103 million in advanced energy project tax credits from the U.S. government and entered into a testing and development agreement with Volkswagen Group’s battery cell manufacturing company, PowerCo SE. The company also won the Reuters Global Energy Transition Award in the R&D Achievement category for its cathode synthesis technology. In the Battery Technology Solutions division, on June 27, NOVONIX (NASDAQ:NVX) was granted a patent in Japan for its all-dry, zero-waste cathode synthesis technology and secured patents in Europe for its graphite/silicon alloy composite material. These patents strengthen NOVONIX’s (NASDAQ:NVX) position in the battery materials and technology sector, particularly in the electric vehicle and energy storage markets. The patented process allows for the production of high-quality single-crystal NMC powders, a cathode powder to develop batteries for power tools such as e-bikes and other electric powertrains, in a more economical and environmentally sustainable manner. According to Hatch, NOVONIX’s (NASDAQ:NVX) cathode synthesis process, can potentially reduce power consumption by almost 25% and can eliminate approximately all of the waste byproduct compared to the conventional process. These factors can reduce costs by an estimated 50% and potentially lower capital costs by an estimated 30%

On August 7, NOVONIX (NASDAQ:NVX) entered into a joint development agreement with CBMM, a Brazilian company specializing in niobium products, to produce nickel-based cathode materials for lithium-ion batteries. Under the agreement, NOVONIX (NASDAQ:NVX) will use its patented all-dry, zero-waste synthesis process to incorporate CBMM’s niobium products into cathode active materials (CAM) to improve performance and reduce costs. The collaboration leverages NOVONIX’s (NASDAQ:NVX) cathode pilot line and testing capabilities, as well as CBMM’s expertise in niobium products, which are known to enhance the stability and durability of cathode materials. The partnership is positioned as a significant step forward in commercializing NOVONIX’s (NASDAQ:NVX)innovative cathode technology and advancing the use of niobium in battery applications.

NOVONIX (NASDAQ:NVX) is strategically well-positioned in the battery technology revolution and is driving critical advancements in the electric vehicle and energy storage sectors. With its pioneering all-dry, zero-waste cathode synthesis technology, strong intellectual property portfolio, and strategic partnerships, NOVONIX (NASDAQ:NVX) is poised to capitalize on the rapidly growing demand for sustainable and high-performance battery materials. The company’s recent achievements, including securing substantial U.S. government tax credits, expanding its global patent protections, and collaborating with industry leaders like Volkswagen and CBMM, underscore its potential for long-term growth and innovation in a market that is essential for a cleaner energy future. In the second quarter, NOVONIX (NASDAQ:NVX) stock was held by 3 hedge funds with stakes worth $1.27 million.

9. Opthea (NASDAQ:OPT)

Number of Hedge Fund Holders: 3  

Market Capitalization as of August 30: $251.04 Million  

Opthea (NASDAQ:OPT) is a biopharmaceutical company focused on developing new treatments for eye diseases, particularly conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These diseases can lead to vision loss and Opthea’s (NASDAQ:OPT) product, called Sozinibercept, is currently being tested in advanced clinical trials to see if it can work better when combined with existing treatments to improve vision more effectively than the standard treatments alone.

Sozinibercept is a novel, first-in-class VEGF-C/D agent designed to enhance the effectiveness of standard anti-VEGF-A therapies in treating wet age-related macular degeneration (AMD). Many wet AMD patients develop resistance to existing treatments. VEGF-C and VEGF-D independently contribute to retinal angiogenesis and vascular leakage, and their inhibition by sozinibercept can prevent these processes, addressing the underlying causes of retinal diseases. As the first potential therapy in 20 years to improve visual outcomes for wet AMD patients, sozinibercept could significantly enhance their quality of life and independence. For the fiscal year ending June 30, Opthea’s (NASDAQ:OPT) operating expenses, which include research and development and administrative costs, rose to $192.1 million, up from $150.4 million. This increase was largely due to the ongoing global Phase 3 clinical trials and CMC activities for its Sozinibercept.

The scientific journal “Ophthalmology and Therapy” also supports the potential of sozinibercept, as a treatment for wet AMD. The journal points out that VEGF-C and VEGF-D play important roles in the development of retinal diseases. Whereas, existing treatments mainly focus on inhibiting VEGF-A, sozinibercept targets VEGF-C and VEGF-D, which could potentially improve treatment outcomes. Wet AMD is affecting millions in the U.S. and Europe. Despite existing treatments, many patients do not achieve optimal vision improvement, underscoring the need for new therapies such as sozinibercept.

Opthea (NASDAQ:OPT) presents a compelling investment opportunity, as the company’s Sozinibercept could overcome the limitations of current treatments, particularly for patients who have developed resistance. With millions of patients affected by these debilitating conditions and the potential to significantly improve their quality of life, sozinibercept could be the first breakthrough therapy in two decades to enhance visual outcomes. In the second quarter, Harmony Gold Mining’s (NYSE:HMY) stock was held by 3 hedge funds with stakes worth $9.94 million. VGI Partners is the largest shareholder in the company with a stake worth $5.61 million as of June 30. Industry analysts have a consensus on the stock’s Buy rating, setting an average share price target at $14.26, which represents a 128.84% upside potential from its current level.

8. Mesoblast (NASDAQ:MESO)  

Number of Hedge Fund Holders: 3  

Market Capitalization as of August 30: $656.93 Million  

Mesoblast (NASDAQ:MESO) is a Melbourne-based biotechnology company specializing in regenerative medicine and cell-based therapies. The company’s two leading products, rexlemestrocel-L (Revascor) and remestemcel-L (Ryoncil), both of which represent massive markets with significant unmet medical needs are in advanced stages of development and have the potential to revolutionize treatments for several life-threatening conditions including inflammatory and cardiovascular diseases.

Rexlemestrocel-L (Revascor) is being developed for chronic heart failure and chronic low back pain, Despite some inconsistency in efficacy data, the company has received an Orphan Drug Designation from the FDA for rexlemestrocel-L’s (Revascor) potential in treating pediatric congenital heart disease. After two prior FDA rejections, on July 24, the FDA accepted the resubmitted biologics license application (BLA) to treat pediatric patients with steroid-refractory acute graft-vs-host disease (SR-aGVHD). If approved, remestemcel-L (Ryoncil) would become the first treatment available for SR-aGVHD in patients under the age of 12. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 7, 2025, for their decision. The drug has already received a Rare Pediatric Disease Designation.

The company’s ongoing dialogue with the FDA has led to progress in refining the potency assays for remestemcel-L (Ryoncil). Remestemcel-L (Ryoncil) is being developed for steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast (NASDAQ:MESO) is advancing remestemcel-L (Ryoncil) into a Phase 3 trial for adults with SR-aGVHD who have failed ruxolitinib treatment. The market for SR-aGVHD, although small presents a critical niche where remestemcel-L (Ryoncil) could become a leading treatment option. With a market penetration strategy that includes both pediatrics and adults, the company could capture a substantial share of this specialized market. If the ongoing trials for rexlemestrocel-L in chronic back pain and heart failure yield positive results, the potential market is vast, with millions of patients suffering from these conditions. The approval for remestemcel-L (Ryoncil) in SR-aGVHD could significantly boost Mesoblast’s (NASDAQ:MESO) valuation.

Mesoblast (NASDAQ:MESO) approach to regenerative medicine, focuses on mesenchymal lineage cells, positions it at the forefront of cellular therapies. These therapies have the potential to address a wide range of conditions, from heart failure to autoimmune diseases, making Mesoblast (NASDAQ:MESO) a key player in the future of medicine. Mesoblast (NASDAQ:MESO) presents a compelling investment opportunity for those with a high-risk tolerance, given the potential for its advanced cellular therapies to address unmet medical needs in large markets. While the road to regulatory approval has been challenging, the company’s perseverance makes it an attractive stock in the biotechnology sector. In the second quarter, Mesoblast’s (NASDAQ:MESO) stock was held by 3 hedge funds with stakes worth $656.93 million. Citadel Investment Group is the largest shareholder in the company with a stake worth $682,703 as of June 30. Industry analysts have a consensus on the stock’s Buy rating, setting an average share price target at $11, which represents a 48% upside potential from its current level.